|RAS and EF-hand domain containing|
|Symbols||; Rab45; FLJ31614|
||This article may be too technical for most readers to understand. (October 2013)|
RASEF belongs to the small GTPase family, which means that it’s able to hydrolyse a molecule of GTP; known for its unusual conformation. In the small GTPase family it is classified in the RAS domain, a special group of oncogenes and oncoproteins that take part in the synthesis of molecules related to cell reproduction.
A feature of RASEF is its N-terminal EF-hand domain with C-terminal Rab-homology domain, that enables it to bind calcium. Lately, RASEF has been studied for its role as an oncoprotein. Investigating which mutations affect it and how we could inhibit them could allow us to fight cancers that have an elevated mortality rate, such as lung cancer.
When studying cancer’s molecular biology we can identify two types of genes that intervene in its development:
- Tumor suppressor genes: Inhibit tumor formation.
- Oncogenes: Stimulate cell proliferation. It is in this group where members of the RAS family are found.
Oncogenes generally code for growth factors and their receptors, enzymes related to transduction signal or for DNA transcription factors. When those genes suffer some kind of mutation or translocation, they can change their conformation and cause a catalytic activity in cell reproduction that is normally inactivated, which causes abnormal cell proliferation. This could provoke a malignant tumor if combined with a separate mutation in a protein's RAS group. 
Nowadays, there is important research in drugs that could eliminate these RAS group mutations but this has not been achieved yet.
We can find the RAS family in the oncogene category, to which the RASEF gene belongs.
Ras / Rab family
RASEF or Rab 45 is classified in the Ras superfamily, which includes small (20kDa) guanosine triphosphatases (GTPases). The basic members of this group of proteins are Ras oncogens. It’s divided into five major families (Ras, Rho, Arf/Sar, Ran and Rab). RASEF is included in the Rab family (the largest family), which is responsible for vesicular traffic of proteins between organelles via endocytotic and secretory pathways. Their function is to make budding from the donor compartment, transport, vesicle fusion and cargo release easier.
RASEF is a 740 amino acids long protein which contains 3 distinct regions: 2 EF hand domains (which in turn contain 2 Calcium bindings and 3 nucleotide bindings -assumed by similarity with other proteins, without direct evidence-), a Coiled Coil region and a C-terminal Rab-homology domain.
N-terminal EF hand domain
Sequence found in RASEF protein that contains 35 amino acids (36 in the second one). The two EF hand domains are consecutively located at the “beginning” of the protein. Its name “N-terminal” indicates an amino group (characteristic of this group of biomolecules, as well as the C- terminal ending). The first one goes from the 8th amino acid to the 42nd, and the other to the 42nd to the 77th. “EF hand” refers to the shape of this domain (similarity with the right hand’s morphology). Ca+2 ions are responsible for this structure, which by binding metals join two alpha helixes.
Coiled coil region
Structural motif in proteins: from two to seven alpha helixes entwined. Each one of these helixes is a repeated 7 amino acid sequence (HPPHCPC), where H refers to hydrophobic amino acids. The position of hydrophobic remains (alpha helix exterior) causes their amphipathic behaviour. The bond between different chains, produced in cytoplasm (aqueous region), is extremely tight, as Van der Waals forces appear between the hydrophobic radicals (H), surrounded by the hydrophilic amino acids (amphipathic molecule). This bond is known as the “Knobs into holes packing”. Coiled coil motif, located in the intermediate region of the protein, is responsible for self-interaction.
C-Terminal Rab-homology domain
Located at the end of the protein (opposite to N-terminal domain), it’s a carboxyl group (COOH). In this region, there are guanine nucleotide bonds to tri-phosphates and di-phosphates. The variability of this domain is responsible for the high appearance of elements needed in the joints between proteins and their targets in the membrane. Both the C-Terminal Rab-homology domain and the intermediate region of the protein are responsible for the intracellular location of the protein (perinuclear region).
RASEF intervenes in a direct manner in biological processes such as protein transport and small GTPase mediated signal transduction. Its molecular functions include GTP binding and calcium ion binding.
As mentioned previously, RASEF has 3 distinct structural regions: the C-terminus Rab domain, the N-terminus EF-hand domain and the self-interacting mid-region. Each of these has an individual function.
The guanine-nucleotide forms of the Rab domain regulate the protein's localization. RASEF is mainly found in the perinuclear region of the cell. In addition, the protein's mid-region also seems to be involved in the perinuclear localization. This could be due to its interaction with membrane compartments. The EF-hand domain’s function still remains to be discovered. However, it is speculated that due to its conformational changes upon binding with Ca2+ ions, and these being responsible for interactions with target molecules; that in cooperation with the Rab-domain, the EF-hand domain's main function is regulating membrane traffic. Over 60 Rab-family GTPase proteins have key roles in membrane traffic regulation. This isn’t surprising given the amount and variety of intracellular compartments, which require a high level of control to ensure a proper delivery and fusion of vesicles at the correct site.
This connects the RASEF protein directly to cell-growth mechanisms, making it susceptible to having a decisive role in the apparition of cancerous cells.
As we have seen, RASEF is involved in cell-growth mechanisms. When its active centre is stimulated by tyrosine kinase (GDP is exchanged by GTP), this part of the oncoprotein adopts a conformation which has much affinity with many effectors.
This induces a huge diversity of biochemical intracellular cascades which, in addition to some other reactions, influence cell behaviour. When these growth factors are altered, the signal cytoplasmatic circuits can not function properly, which could provoke serious pathologies like cancer. The constitutively active form of Ras oncoprotein is expressed in high levels in bladder carcinomas, leukemias, colon, breast, lung and skin cancers.
Some researchers have discovered that Ras and Ef-hand domain containing proteins are commonly overexpressed in primary lung cancers and its intervention is crucial for the proliferation and survival of cancerous cells. Apart from binding calcium ions in the N-terminus, RASEF plays a significant role in lung cancer cell-growth. This occurs because of its interaction with ERK (extracellular signal-regulated kinase) molecules involved in the regulation of meiosis, mitosis, and postmitotic functions in differentiated cells, whose pathway can be activated by carcinogens or viral infections. .
There is ongoing research that is studying the possibility of using RASEF as a clinically promising prognostic biomarker and therapeutic target for lung cancer. Some recent studies have revealed the viability of using RASEF as a target for this disease.
Also, a segregation study in families with uveal and cutaneous melanoma identified a potential locus harboring a tumor-suppressor gene (TSG). One of the genes in this area (9q21), RASEF, was then analyzed as a candidate TSG, but the lack of point mutations and copy number changes could not confirm this. Nowadays, the RASEF gene has been investigated for potential mutations and gene silencing by promoting methylation in uveal melanoma. It appears to be the mechanism targeting RASEF in uveal melanoma, and allelic imbalance at this locus supports a TSG role for the Ras and Ef-hand domain containing.
- "RASEF (human)". Protein Page. PhosphoSitePlus. ;
- "Entrez Gene: RAS and EF-hand domain containing".
- Sweetser DA, Peniket AJ, Haaland C, Blomberg AA, Zhang Y, Zaidi ST, Dayyani F, Zhao Z, Heerema NA, Boultwood J, Dewald GW, Paietta E, Slovak ML, Willman CL, Wainscoat JS, Bernstein ID, Daly SB (November 2005). "Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia". Genes Chromosomes Cancer 44 (3): 279–91. doi:10.1002/gcc.20236. PMID 16015647.
- Shintani M, Tada M, Kobayashi T, Kajiho H, Kontani K, Katada T (June 2007). "Characterization of Rab45/RASEF containing EF-hand domain and a coiled-coil motif as a self-associating GTPase". Biochem. Biophys. Res. Commun. 357 (3): 661–7. doi:10.1016/j.bbrc.2007.03.206. PMID 17448446.
- Tietz Textbook of Clinical Chemistry[page needed]
- Tietz Textbook of Clinical Chemistry[page needed]
- Tietz Textbook of Clinical Chemistry[page needed]
- Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y (February 2010). "Rho GTPases in hematopoiesis and hemopathies". Blood 115 (5): 936–47. doi:10.1182/blood-2009-09-198127. PMC 2817638. PMID 19965643.
- Rojas AM, Fuentes G, Rausell A, Valencia A (January 2012). "The Ras protein superfamily: evolutionary tree and role of conserved amino acids". J. Cell Biol. 196 (2): 189–201. doi:10.1083/jcb.201103008. PMC 3265948. PMID 22270915.
- http://www.rcsb.org/pdb/protein/Q8IZ41?evtc=Suggest&evta=UniProtGene%20Names&evtl=OtherOptions[full citation needed]
- Branden C, Tooze J (1999). "Chapter 2: Motifs of protein structure". Introduction to Protein Structure. New York: Garland Pub. pp. 24–25. ISBN 0-8153-2305-0.
- Mason JM, Arndt KM (February 2004). "Coiled coil domains: stability, specificity, and biological implications". Chembiochem 5 (2): 170–6. doi:10.1002/cbic.200300781. PMID 14760737.
- CRICK FH (November 1952). "Is alpha-keratin a coiled coil?". Nature 170 (4334): 882–3. doi:10.1038/170882b0. PMID 13013241.
- Burkhard P, Stetefeld J, Strelkov SV (February 2001). "Coiled coils: a highly versatile protein folding motif". Trends Cell Biol. 11 (2): 82–8. doi:10.1016/S0962-8924(00)01898-5. PMID 11166216.
- Chavrier P, Gorvel JP, Stelzer E, Simons K, Gruenberg J, Zerial M (October 1991). "Hypervariable C-terminal domain of rab proteins acts as a targeting signal". Nature 353 (6346): 769–72. doi:10.1038/353769a0. PMID 1944536.
- Oncología Clínica, M González
- Oncología Clínica, M González[full citation needed]
- Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y (August 2013). "RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer". Mol. Cancer Res. 11 (8): 937–51. doi:10.1158/1541-7786.MCR-12-0685-T. PMID 23686708.
- Maat W, Beiboer SH, Jager MJ, Luyten GP, Gruis NA, van der Velden PA (April 2008). "Epigenetic regulation identifies RASEF as a tumor-suppressor gene in uveal melanoma". Invest. Ophthalmol. Vis. Sci. 49 (4): 1291–8. doi:10.1167/iovs.07-1135. PMID 18385040.